Evidence map›Paper›PMID 42010496›Full record

Observational studyBMC infectious diseases2026

Towards precision dosing of contezolid: moderate hepatic impairment increases plasma concentration of contezolid in anti-tuberculosis treatment.

Hong Lu, Manjiao Fu, Qunzhi Shi, Lin Liu, Ying Zeng, Pan Yan, Pengyu Li

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hong Lu *Department of Pharmacy, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, 410004, China.
Manjiao Fu *Tuberculosis Intensive Care Unit, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, 410004, China.
Qunzhi ShiDepartment of Pharmacy, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, 410004, China.
Lin LiuDepartment of Pharmacy, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, 410004, China.
Ying ZengDepartment of Pharmacy, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, 410004, China.
Pan YanDepartment of Pharmacy, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, 410004, China.
Pengyu LiDepartment of Pharmacy, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, 410004, China. lipengyu28@163.com.

Funding

Innovative Province Construction Special Project of Hunan Province, China 2023SK4071Key Guidance Project of Hunan Provincial Health Commission, China C202303086429Natural Science Foundation of Hunan Province of China 2025JJ60773Natural Science Foundation of Hunan Province of China 2025JJ80583
6 · The paper itself

Abstract

backgroundContezolid is a novel oxazolidinone antibiotic with potent antimicrobial activity against Mycobacterium tuberculosis. To date, the plasma concentration profile of contezolid and its influencing factors remain poorly characterized.

methodsThis prospective observational study included patients who were diagnosed as tuberculosis and received contezolid (800 mg every 12 h) between July 2024 and October 2025. All patients underwent therapeutic drug monitoring to obtain steady-state trough plasma concentrations (Cmin) of contezolid. Demographic characteristics and laboratory examinations were recorded. The factors associated with Cmin of contezolid were explored.

resultsA total of 25 patients were included in the study. The Cmin of contezolid ranged from 0.11 mg/L to 18.01 mg/L. Total bilirubin was identified as the key factor influencing the Cmin of contezolid while no significant associations were observed with age, sex, albumin, aspartate aminotransferase, or estimated glomerular filtration rate. Furthermore, patients were grouped by their liver function, and the result revealed that moderate hepatic impairment induced a significant increase of Cmin from 2.98 ± 4.19 mg/L to 9.69 ± 4.95 mg/L.

conclusionThe Cmin of contezolid exhibits substantial interindividual variability. Close monitoring is therefore recommended in patients with hepatic impairment to guide potential dose adjustments.

Indexed as

Antitubercular AgentsOxazolidinonesTuberculosisAdultDrug MonitoringFemaleHumansMaleMiddle AgedMycobacterium tuberculosisProspective StudiesAntitubercular AgentsOxazolidinonesContezolidHepatic impairmentPlasma concentrationTotal bilirubinTuberculosis

Identifiers

PMID42010496
PMCPMC13231784

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.